eFFECTOR Therapeutics, Inc.

Locust Walk Acquisition Corp (Nasdaq: LWAC), a blank-check company sponsored by Locust Walk Partners, filed an 8-K with the SEC on May 27, 2021, disclosing its proposed business combination with eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company developing translation regulator therapies targeting the eIF4F pathway in oncology. The SPAC completed its initial public offering in 2020 with a mandate focused on the life sciences sector. The merger subsequently closed, bringing eFFECTOR to the public markets on Nasdaq under the ticker EFTR, where the company continues to advance its oncology pipeline. To access the full filing history, sponsor data, and transaction details for LWAC and hundreds of other SPACs, sign up for a free account at SpacDesk.